27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Biotech stocks saw modest gains this week, with earnings providing a boost even as clinical trial results elicited a mixed reaction.
Eli Lilly And Co (NYSE:LLY), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Gilead Sciences, Inc. (NASDAQ:GILD) are among some prominent biotechs that reported solid results and offered optimistic assessments for thenear-to-medium term.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Looking ahead to the upcoming week, biotech investors should watch for the following catalytic events.
Conferences
- Global Experts Meeting On Diabetes, Hypertension & Metabolic Syndrome: July 30-31 in Melbourne, Australia.
- 8th International Conference on Geriatrics Gerontology & Palliative Nursing: July 30-31 in Barcelona, Spain.
- International Pan Pacific Conference of ART & Perinatology: Aug. 3-5 in Las Vegas.
PDUFA Dates
FDA is set to announce its verdict on Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)'s rare neuroendocrine tumor treatment candidate Azedra on Sunday, July 30.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) and AbbVie Inc (NYSE:ABBV) await the FDA's ruling on Elagolix for endometriosis-associated pain. Based on the three-month extension in the review period announced by the FDA on April 10, the decision could come in July or early August.
See Also: Tricida Post-IPO Run-up Makes Goldman Wary
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Earnings
Monday
- Tandem Diabetes Care Inc (NASDAQ:TNDM) (after the close)
- GenMark Diagnostics, Inc (NASDAQ:GNMK) (after the close)
- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) (before the open)
Tuesday
- Pulse Biosciences Inc (NASDAQ:PLSE) (after the close)
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) (after the close)
- NewLink Genetics Corp (NASDAQ:NLNK) (after the close)
- Incyte Corporation (NASDAQ:INCY) (before the open)
- Medpace Holdings Inc (NASDAQ:MEDP) (before the open)
- Hologic, Inc. (NASDAQ:HOLX) (after the close)
- Pfizer Inc. (NYSE:PFE) (before the open)
- NuVasive, Inc. (NASDAQ:NUVA) (after the close)
- Qiagen NV (NYSE:QGEN)
- Illumina, Inc. (NASDAQ:ILMN) (after the close)
Wednesday
- Conatus Pharmaceuticals Inc (NASDAQ:CNAT) (after the close)
- Amarin Corporation plc (ADR) (NASDAQ:AMRN) (before the open)
- ArQule, Inc. (NASDAQ:ARQL) (before the open)
- AtriCure Inc. (NASDAQ:ATRC) (after the close)
- AxoGen, Inc (NASDAQ:AXGN)
- Blueprint Medicines Corp (NASDAQ:BPMC) (before the open)
- EXACT Sciences Corporation (NASDAQ:EXAS) (after the close)
- Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) (after the close)
- Globus Medical Inc (NYSE:GMED) (after the close)
- IDEXX Laboratories, Inc. (NASDAQ:IDXX) (before the open)
- Clovis Oncology Inc (NASDAQ:CLVS) (after the close)
- DURECT Corporation (NASDAQ:DRRX) (after the close)
- Exelixis, Inc. (NASDAQ:EXEL) (after the close)
Thursday
- Genomic Health, Inc. (NASDAQ:GHDX) (after the close)
- Obalon Therapeutics Inc (NASDAQ:OBLN) (before the open)
- Acceleron Pharma Inc (NASDAQ:XLRN) (after the close)
- Insmed Incorporated (NASDAQ:INSM) (before the open)
- Seres Therapeutics Inc (NASDAQ:MCRB) (before the open)
- Curis, Inc. (NASDAQ:CRIS) (before the open)
- Acorda Therapeutics Inc (NASDAQ:ACOR) (before the open)
- AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) (after the close)
- Agios Pharmaceuticals Inc (NASDAQ:AGIO) (before the open)
- Becton Dickinson and Co (NYSE:BDX) (before the open)
- Arbutus Biopharma Corp (NASDAQ:ABUS) (after the close)
- Emergent Biosolutions Inc (NYSE:EBS) (after the close)
- T2 Biosystems Inc (NASDAQ:TTOO) (after the close)
- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) (after the close)
- Pacific Biosciences of California (NASDAQ:PACB) (after the close)
- Nevro Corp (NYSE:NVRO) (after the close)
- Cerus Corporation (NASDAQ:CERS) (after the close)
- TESARO Inc (NASDAQ:TSRO) (after the close)
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN) (before the open)
- Revance Therapeutics Inc (NASDAQ:RVNC) (after the close)
- Pacira Pharmaceuticals Inc (NASDAQ:PCRX) (before the open)
- Zoetis Inc (NYSE:ZTS) (before the open)
- ResMed Inc. (NYSE:RMD)
- Insulet Corporation (NASDAQ:PODD) (after the close)
- Glaukos Corp (NYSE:GKOS) (after the close)
- Repligen Corporation (NASDAQ:RGEN) (before the open)
- Epizyme Inc (NASDAQ:EPZM) (before the open)
- Aratana Therapeutics Inc (NASDAQ:PETX)
IPO
Bionano Genomics, an instrumentation company operating in the genome analysis space, is proposing to offer 3.35 million shares in an IPO, with the price range estimated between $8 and $10. The company intends to list its shares on the Nasdaq under the ticker symbol "BNGO."
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.